Lassa virus (LASV) is a BSL-4 restricted agent. To allow study of infection by LASV under BSL-2 conditions, we generated a recombinant virus in which the LASV glycoprotein (Gp) was placed on the backbone of lymphocytic choriomeningitis virus (LCMV) Cl13 nucleoprotein, Z and polymerase genes (rLCMV Cl13/ LASV Gp). The recombinant virus displayed high tropism for dendritic cells following in vitro or in vivo infection. Inoculation of immunocompetent adults resulted in an acute infection, generation of virusspecific CD8
Introduction
Lassa virus (LASV), the agent of a severe and often fatal hemorrhagic illness known as Lassa fever (LF), is endemic in West Africa and estimated to infect more than 300,000 individuals yearly, hospitalizing 100,000 and causing 20,000 or more deaths. LASV has entered Europe and America (Freedman and Woodall, 1999; Holmes et al., 1990; Isaacson, 2001; McCormick and Fisher-Hoch, 2002; Schmitz et al., 2002) via travelers incubating the virus. As a Category A Select Agent, LASV is a potential bioterrorist threat (Borio et al., 2002 ).
An early host immune response to LASV is crucial for survival (Flatz et al., 2010; Geisbert and Jahrling, 2004; McCormick and Fisher-Hoch, 2002) . Infected individuals with viral titers of 9 logs/ ml blood or above, fail to mount an effective innate/adaptive immune response and invariably die, whereas those with blood titer of 8 logs of virus or less do respond immunologically with a T cell response and survive (Schmitz et al., 2002) . Earlier we documented that alpha-dystroglycan (α-DG) was the receptor for LASV and other Old World arenaviruses like lymphocytic choriomeningitis virus (LCMV) (Cao et al., 1998; Oldstone and Campbell, 2011; Spiropoulou et al., 2002) . Further, among cells of the immune system α-DG is preferentially located on DCs ( 499% of α-DG in the immune system is found on DCs) Oldstone and Campbell, 2011; Sevilla et al., 2000; Sevilla et al., 2004) . DCs are a preferred target of wild-type (wt) LASV which impairs DC function (Baize et al., 2004; Baize et al., 2006; Mahanty et al., 2003; Pannetier et al., 2011) .
LASV and LCMV are members of the Old World arenavirus family and contain a similar two-RNA segment organization, four viral genes and genome structure (Buchmeier et al., 2007) . The glycoprotein (Gp) and nucleoprotein (NP) are encoded on the short RNA segment, while the Z matrix protein and L polymerase are encoded on the long RNA. With the recent advent of a reverse genetics for the arenaviruses Emonet et al., 2009) it is possible to construct a recombinant (r) LCMV backbone expressing the LASV glycoprotein (Gp), thereby allowing the investigation of LASV Gp binding, cell entry and replication in the context of a viral infection.
Utilizing the backbone of LCMV Armstrong (ARM) 53B, a recombinant virus expressing LASV Gp (Josiah strain) was made by Rojek and colleagues to study LASV Gp-mediated cell entry (Rojek et al., 2008) . They discovered that LASV entered cells by a unique endocytic pathway distinct from the clathrin-dependent endocytosis used by pathogenic New World arenaviruses. However, this recombinant was not suitable for in vivo animal studies and thus not useful for dissecting LASV pathogenesis. For that reason we turned to use of LCMV Cl13 as the backbone for constructing rLCMV/LASV Gp.
The parental LCMV ARM and its variant strain LCMV Cl13 differ from each other by six nucleotides and three amino acids of which only two, one in the Gp spike at aa 260 (ARM/Cl13: Phe/Leu) and one in the polymerase gene aa 1079 (ARM/Cl13: Lys/Glu) determine heightened entry into DCs (Gp1 Leu) and heightened replication (polymerase Glu) of LCMV Cl13 over that observed with LCMV ARM. Further, these two amino acid differences determine whether an acute viral infection is controlled by cytotoxic T (CTL) cells (ARM) or whether an inadequate generation of T cells occurs followed by their exhaustion occurs leading to viral persistence (Cl13) (Barber et al., 2006; Brooks et al., 2006; Wherry, 2011; Zajac et al., 1998) . To take advantage of the enhanced replication of LCMV Cl13 in DCs to study LASV Gp-mediated pathogenesis, we used reverse genetics to construct a novel rLCMV Cl13/LASV Gp using the Cl13 backbone.
Here we report that the rLCMV Cl13/LASV Gp replicates in multiple tissues of adult mice and induces the generation of robust virus-specific CD8 + CTLs. Removal of immune cells by use of Rag2 
Results

Polymerase of LCMV Cl13 provides enhanced replication of LCMV when compared to the polymerase of LCMV ARM
Our first series of experiments determined the efficiency of LCMV replication comparing the polymerase of LCMV Cl13 with that of LCMV ARM. The L RNA which contains the Z gene and the polymerase gene from LCMV ARM or from LCMV Cl13 was swapped with the S RNA gene of LCMV Cl13 or LCMV ARM, respectively, as previously reported (Popkin et al., 2011; Rojek et al., 2008) . Since the other gene residing on the L RNA, the Z gene and its protein, is identical between LCMV Cl13 and LCMV ARM, we were essentially evaluating the difference provided by the single amino acid mutation at aa 1079 of Glu for LCMV Cl13 compared to Lys for LCMV ARM. Utilizing cloned established murine dendritic cell lines P4H1 and 9 M (Nayak, Schmedt, Sullivan, and Oldstone, manuscript in preparation 2013), we noted that reassorted virus containing the polymerase of LCMV Cl13 replicated 1.5 to 2 logs greater than did the recombinant virus containing the polymerase of LCMV ARM (Fig. 1, Panels A and B) . Interestingly, despite being linked to the Gp1 of the S RNA of LCMV ARM which is decidedly inferior for attachment and entry compared to Gp1 of LCMV Cl13 (Sullivan et al., 2011) , the replication of S ARM/L Cl13 was equivalent to the amount of infectious virus produced by the wild-type LCMV Cl13 (S Cl13/L Cl13) (Fig. 1A,B) , again revealing the greater efficiency in replication of LCMV Cl13 polymerase. These results lead us to generate and characterize a recombinant LCMV Cl13 expressing the envelope Gp of LASV Josiah strain (rLCMV Cl13/LASV Gp).
Generation and characterization of rLCMV Cl13/LASV Gp
To be able to investigate LASV at BSL-2 level in the context of a productive infection outside of BSL-4 facility, we utilized published reverse genetics technology to generate a recombinant LCMV Cl13 where the LASV Gp substituted for LCMV Cl13 Gp (Rojek et al., 2008) . Briefly, BHK cells were co-transfected with plasmids pCL and pCNP, together with plasmids that allowed for Pol I-mediated intracellular synthesis of the L and S RNA species. We infected Vero and A549 cells and collected supernatants at 48, 72, and 96 h post-infection to test for presence of replicating infectious rLCMV Cl13/LASV Gp ( Fig. 1: C,D) . The infection kinetics of rLCMV Cl13/ LASV Gp virus were similar to that of the parental LCMV Cl13. Furthermore, infecting the P4H1 DC line with rLCMV Cl13/LASV Gp resulted in a similar infection to that of Cl13 (Fig. 1D) , with 1.5 to 2 logs greater replication than LCMV ARM. Similar enhanced replication of 1-2 logs with viruses containing the polymerase of Cl13 over those with polymerase of ARM occurred in 9 M cloned DCs (data not shown). Interestingly this enhanced replication of Cl13 and Cl13 polymerase-containing viruses, while being observed in DC lines, was not observed in VeroE6 (Fig. 1C ) or A549 and BHK cells (data not shown).
Alpha-dystroglycan (α-DG) has been shown to be the receptor for LASV (Cao et al., 1998; Spiropoulou et al., 2002) . We next determined whether the infection with rLCMV Cl13/LASV Gp proceeded through α-DG by incubating the viruses with soluble α-DG prior to initiating infection. Previously we demonstrated that LCMV Cl13 entry into cells bearing α-DG on their surfaces was blocked in a dose-dependent manner by soluble α-DG (Cao et al., 1998) and virus entry was dependent on the Gp of Cl13 (Sullivan et al., 2011) . Similar blunting occurred when soluble α-DG was incubated with rLCMV Cl13/LASV Gp ( Fig. 1E ), while titers of virus produced were dependent on α-DG blockade ( Fig. 1F) indicating that the recombinant virus bearing LASV Gp can be used at BSL-2 level for LASV Gp-mediated binding, entry, and in vitro replication studies.
Replication of rLCMV Cl13/LASV Gp in vivo in adult mice
We next injected rLCMV Cl13/LASV Gp into adult immunocompetent H-2 b C57BL/6 mice and studied viral replication in vivo.
Employing a wide dose range from 2 Â 10 5 PFU intraperitoneally (i.p.) to 2 Â 10 6 and 4 Â 10 6 PFU intravenously (i.v.) of rLCMV Cl13/ LASV Gp, we noted limited viral replication (PFU/gm tissue) in liver, spleen, kidney, and sera (PFU/ml) (Table 1A -viral dose indicated). Tissue and serum viral titers dropped significantly by 1 to 3 logs between day 5 post-infection (PI) and day 7/8 PI with the majority of mice completely purging virus at this time. These results suggested the likelihood of a strong antiviral T-cell response limiting viral replication and clearing the acute infection.
To test this possibility we utilized Rag2 −/− mice on the same C57BL/6 background inoculated with 4 Â 10 6 PFU of rLCMV Cl13/ LASV Gp. As shown in Table 1A , Rag2 −/− mice exhibited an increase in tissue and serum viral titers from day 5 to day 7/8, indicating that the immune response cleared the infection. Low viral titers in C57BL/6 mice precluded the ability to detect viral antigens in most tissues while, in contrast, infection of Rag2
mice yielded significant expression of viral antigen in tissues (Table 1B) . Of interest was the location of viral antigen at day 5 to the marginal zone of the white pulp of the spleen. This anatomical location of recombinant LCMV containing the LASV Gp is identical to that observed earlier (Sevilla et al., 2004; Smelt et al., 2001) which was dependent on the Gp of LCMV Cl13. Thus, early during infection LASV Gp mimics LCMV Cl13 Gp on entry in the marginal zone and into white pulp DCs (Table 1B , lower left panel) which is dependent on expression of αDG on DCs Sevilla et al., 2000; Sevilla et al., 2004; Smelt et al., 2001; Sullivan et al., 2011) .
Dendritic cells (DCs) are permissive to rLCMV Cl/LASV Gp infection
We next infected groups of four Rag2 −/− mice with rLCMV Cl13/ LASV Gp and focused on rLCMV Cl13/LASV Gp infection of DCs.
Five and eight days post-infection, both plasmacytoid DCs obtained from the bone marrow and conventional DCs from the spleen were assayed for expression of viral antigen using a monoclonal antibody that detected NP viral antigen and flow cytometry. As shown in Fig. 2 , 29% to 32% of DCs expressed rLCMV Cl13/LASV Gp virus during acute infection at day 8. Replication of infectious rLCMV Cl13/LASV Gp from isolated DCs was observed by infectious center assay (data not shown).
rLCMV Cl13/LASV Gp generates virus-specific MHC-restricted CTL in adult immunocompetent mice
We next measured the generation and efficiency of virusspecific MHC-restricted CTLs. To determine MHC-restriction, we infected syngeneic H-2 b MC57 and allogeneic Balb Cl7 H-2 d targets with an MOI of 1 of rLCMV Cl13/LASV Gp. We first insured that these target cells were infected by and express rLCMV Cl13/LASV Gp by immunofluorescent staining for the viral NP (Fig. 3A) . We then performed a 51 Cr release assay using splenic lymphocytes from C57BL/6 mice primed 7 days earlier with 1 Â 10 5 PFU of rLCMV Cl13/LASV Gp i.p. The results showed, in a dose-dependent manner using different ratios of effector to target cells, that a robust virus-specific MHC-restricted CTL response was generated ( only 61.5% homologous and LCMV ARM and LCMV Cl13 share the exact same Gp CTL epitopes. As shown in Fig. 3C , the complete LCMV Gp expressed using a vaccinia virus (VV) promoter (Whitton et al., 1988b) is not recognized by CTL generated against rLCMV/ LASV Gp indicating that LASV Gp epitope(s) lie in the 38.5% nonhomologous amino acid sequence between Gp of LASV and that of LCMV Cl13. As expected CTLs generated against either LCMV Cl13/ LASV Gp or VV expressing whole LCMV NP recognized the NP epitope 396-404. The last experiment in this series used tetramers to NP 396-404 to determine the efficiency of the generated CTLs in terms of the number and amount of inflammatory cytokines released. As shown in Fig. 3D , CTLs released interferon-γ, IL-2, and TNF equivalently when generated against either rLCMV/LASV Gp or the parental LCMV. intracranially resulted in a lethality of over 85%, while in contrast inoculation of parental LCMV caused a lethality of o20%. We then inoculated H-2 q (SWR/J) mice with rLCMV Cl13/LASV Gp and had a survival rate of 4 75%. Such H-2 q virus-inoculated mice carried virus throughout their life. When sacrificed at 42 days PI, analysis of tissues indicated viral titers of 10 5 to 10 6.5 in spleen, kidney, brain, lung, heart, liver, and sera. Tissues harvested from these organs, fixed in 4% paraformaldehyde, sectioned and stained with monoclonal antibody to viral NP antigen revealed widespread evidence of viral replication in these tissues similar to pictures in Table 1B and titers in Table 1A .
We have previously shown that adoptive transfer of MHCrestricted immune memory cells harvested from the spleen were able to clear virus from life-long virus carriers whose infection was initiated similarly at birth with either LCMV ARM or LCMV Cl13 (Berger et al., 2000; Oldstone et al., 1986; Tishon et al., 1993) . In the last series of experiments, we tested whether immune memory cells generated to rLCMV Cl13/LASV Gp that had demonstrated robust virus-specific MHC-restricted CTL activity (Fig. 3) were able to clear rLCMV Cl13/LASV Gp virus carrier mice. For these experiments we infected groups of 9 newborn C57BL/6 mice each with 1 Â 10 3 PFU of either LCMV Cl13 or rLCMV Cl13/LASV Gp i.c. The lower dose of virus delivered i.c. resulted in increased survival of the mice following infection. All mice developed a lifelong persistent infection as judged by presence of 10 4.5 to 10 5 logs of virus in their sera. When such persistently infected mice were 30 days old, they each received 2 Â 10 7 immune memory splenocytes i.v. harvested at day 42 post-infection from C57BL/6 mice immunized with rLCMV Cl13/LASV Gp. Unexpectedly, as shown in Fig. 4 , rLCMV Cl13/LASV Gp persistently infected mice failed to clear virus when receiving adoptive transferred CTLs generated against rLCMV Cl13/LASV. Virus persisted as long as 160 days posttransfer (last time-point analyzed). In contrast, similar CTLs generated from rLCMV Cl13/LASV successfully purged virus from all LCMV Cl13 virus carriers by 30 days post-transfer of CTL.
Discussion
Here we report the generation of a recombinant LCMV expressing the Gp of LASV and make four observations. First, using the LCMV backbone, the optimal recombinant virus contains the polymerase gene of LCMV Cl13 which enhances its replication in DCs (Fig. 1D) , and this rLCMV Cl13/LASV Gp virus shows tropism and replication for DCs in vivo (Fig. 2) . Second, the rLCMV Cl13/ LASV Gp replicates in mouse and generates a robust CTL response that clears the viral infection (Fig. 3, Table 1 ). Third, although the CTLs generated against rLCMV Cl13/LASV Gp are competent in cleansing virus from an acute infection, they are ineffectual upon adoptive transfer in terminating a persistent infection initiated by rLCMV Cl13/LASV Gp (Fig. 4) . Lastly the rLCMV Cl13/LASV Gp can be used at BSL2 for both in vitro and in vivo studies of the role of LASV Gp in LASV pathogenesis.
Generating genetic reassortant viruses between LCMV ARM and LCMV Cl13 indicated the advantage of Cl13 polymerase over that of ARM polymerase for enhanced replication in DCs (Fig. 1A,  B) . This led us to construct a recombinant virus bearing LASV Gp that included the LCMV Cl13 polymerase. The rLCMV Cl13/LASV Gp demonstrated a dependency of LASV Gp for binding to α-DG and for cell entry as soluble α-DG was able to blunt infection by a LCMV Cl13/LASV Gp virus in a dose-dependent fashion. Interesting was the observation of a difference in viral replication between LASV Gp recombinant using Cl13 backbone over ARM backbone with infection of DCs but not with infection of several cell lines including Vero, A549 and BHK cells. Injection of rLCMV Cl13/LASV Gp into C57BL/6 mice led to an initial systemic infection that was curtailed by a robust H-2 b MHCrestricted CTL response. Analysis of this response indicated CTLs were generated against LCMV Cl13 NP as well as LASV Gp amino acid sequences. The Gp sequences recognized by CTLs generated to rLCMV Cl13/LASV Gp are distinct from LCMV H-2 b restricted immunodominant Gp aa 33-41, Gp aa 276-286 and subdominant Gp aa 92-101 and Gp aa 118-125, as the full length LCMV Gp containing these sequences was not recognized by CTL made to the recombinant virus bearing LASV Gp when expressed on target cells using vaccinia virus vectors. The LASV epitopes restricted by MHC H-2 b recognized by CTLs generated to LASV Gp must reside in the 38.5% of the LASV Gp sequence that is different from the LCMV Cl13 or ARM Gp. These differences do not comprise any predominant region of the Gp, but are scattered throughout the sequence. As such, it is difficult to determine which specific sequences within the LASV Gp elicit the CTL responses seen here. Earlier genetic studies of LCMV genes showed that CTL responses to LCMV were preferentially generated to the Gp and NP with no detectable response to the Z protein and only one epitope was noted in the polymerase protein (Riviere et al., 1986; Whitton et al., 1988a; Whitton et al., 1988b) . As such, LASV Gp H-2 b restricted CTL are likely responsible for the additional level of CTL response to the recombinant LASV noted over the observed CTL response to NP 396-404 alone. Further, the observed generation of a vigorous antiviral immune response to LASV Gp suggests that the rLCMV Cl13/LASV Gp might be evaluated as a potential vaccine candidate against LASV infection. Persistent lifelong infection can be induced in mice infected either at birth or in utero with rLCMV Cl13/LASV Gp. This mimics the naturally occurring LASV persistent infection of most rodents in LASV endemic areas. Unexpectedly, adoptive transfer of MHCrestricted immune memory CTLs generated against rLCMV Cl13/ LASV Gp was unable to clear a persistent infection induced by the recombinant virus. However, MHC-restricted immune memory CTLs generated to LCMV Cl13 were able to clear the persistent infection due to rLCMV Cl13/LASV Gp. These results suggest something unique in the environment of mice infected with the LASV recombinant virus that prevents clearance of persistent viral infection. Previous studies utilizing LCMV in which the immunodominant H-2 b restricted CTL epitope for NP 396-404 was knocked out (Lewicki et al., 1995a; Lewicki et al., 1995b) or in which NP 396-404 specific CTLs were adoptively transferred into mice indicated the NP 396-404 CTLs were themselves sufficient to terminate the persistent virus infections. Our analysis of the functional activity of CTLs generated against NP 396-404 using either rLCMV Cl13/LASV Gp or CL13 showed that these CTLs were equally capable of lysing infected targets and expressing the proinflammatory cytokines TNFα and IFN-γ (Fig. 3C,D) . Thus, it is unclear why the CTLs generated by recombinant virus infection were ineffectual in in vivo clearance. Perhaps either an environmental difference in the persistently infected mouse, akin to our recent report in the TLR7 −/− mouse upon LCMV infection (Walsh et al., 2012) , or a requirement for other immune effector cells differentially elicited by the two viruses is involved. Lastly, the infection of pDCs or cDCs by LASV Gp-bearing recombinant virus in vitro and in vivo should allow a biochemical analysis of virus-DC interactions mediated by the LASV Gp. This is important as DCs are one of the primary cells infected by wild type LASV and LASV infection of human DCs has been demonstrated to alter DC function (Baize et al., 2004; Baize et al., 2006; Mahanty et al., 2003; Pannetier et al., 2011) . Incorporation of the LASV Gp into the LCMV Clone 13 backbone enabled us to replicate the tropism of LASV for DCs without having to incorporate any of the other LASV transcriptional proteins, mitigating the biosafety concerns inherent in LASV work. It is important to note that the overall immune responses against wild-type LASV in infected individuals will likely vary from the immune responses against rLCMV Cl13/LASV Gp shown here owing to the differences between the other LASV and LCMV proteins (NP, Z, and polymerase). However, the rLCMV Cl13/LASV Gp virus will serve as a useful tool for uncovering mechanisms of cell binding, entry, infection and immune subversion initiated by the Gp of LASV in DCs in a BSL-2 environment rather than the highly restrictive BSL-4 environment required by work with the wild-type LASV.
Materials and methods
Cell lines and reagents
BHK-21 cells were grown in Dulbecco's Modified Essential Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 100 μg/mL penicillin-streptomycin (Gibco), 2 mM L-glutamine (Gibco), 0.24% glucose (w/v), and 7% tryptose phosphate broth solution (Sigma). VeroE6 cells were propagated in Eagle's minimal essential medium (MEM) supplemented with 7% FBS, 100 μg/mL penicillin-streptomycin, and 2 mM L-glutamine. MC57 and BALB/c17 cells were propagated in DMEM supplemented with 10% FBS, 100 μg/mL penicillin-streptomycin, and 2 mM L-glutamine. Dendritic cell ) by intracellular staining for NP antigen and flow cytometry. As the figure shows, rLCMV Cl13/LASV Gp and Cl13 viruses can be found in equivalent amounts in both DC subsets on day 5, and increase significantly by day 8 post-infection. Percentages shows are mean 7standard error of the mean for three independent experiments, with two representative experiments shown. lines P4H1 and 9 M were a gift from Bishnu Nayak (Genomics Institute of the Novartis Foundation) and were propagated in RPMI 1640 medium supplemented with 10% FBS, 100 μg/mL penicillinstreptomycin, 2 mM L-glutamine, 50 μM β-mercaptoethanol, 1% (v/v) sodium pyruvate, and 20 μg/mL GM-CSF (Peprotech).
Mouse strains C57BL/6 and Balb/c mice were obtained from the Rodent Breeding Colony at The Scripps Research Institute. SWR/J mice were purchased from The Jackson Laboratory (Bar Harbor, Maine).
Virus strains and stocks
All recombinant viruses used were generated using reverse genetics technology as described previously Emonet et al., 2009) . To produce rLCMV Cl13/LASV Gp virus, cloning of the LASV Josiah strain Gp was performed as described previously for rLCMV ARM/LASV Gp (Rojek et al., 2008) . Viral stocks were generated by passage in BHK-21 cells by infecting at low multiplicity of infection (MOI¼ 0.01) for 48 h and collecting virus-containing culture supernatant followed by cell debris centrifugation at 2000 Â g for 10 min. at 4 1C. Viral titers were assessed by immune focus assay (Urata et al., 2010) or by plaque assay (Sullivan et al., 2011) . Recombinant vaccinia viruses expressing the LCMV nucleoprotein or glycoprotein used in chromium release assays were generated as described previously (Whitton et al., 1988b) .
Virus infections
For cell lines, viral infections were done by adding virus to the cell culture at a multiplicity of infection (MOI) of 0.1 for 1 h. Virus was then removed, cells washed, and fresh media was added to the culture. Viral titers were measured in the supernatants at various times post-infection. For in vivo studies, mice were injected either intraperitoneally (i.p.) with a low dose (non-immunosuppressive) or intravenously (i.v.) with a high dose (immunosuppressive) of virus as indicated. Viral titers were assessed in sera and tissues at the indicated timepoints post-infection as above. For intracranial (i.c.) infection, virus was diluted to the required dose in 30 μL final volume, and 30 μL was administered to anesthetized mice by injection at the midline of the skull using a stepper syringe with a 30 gauge needle and an attached depth stopper.
Generation of persistently infected mouse and adoptive immune memory T-cell transfer experiments
To generate persistently infected mice, newborn mice (o24 h old) were injected with 1 Â 10 3 PFU of virus intracranially (i. Cr using a gamma counter as reported (Sullivan et al., 2011; Walsh et al., 2012; Welch et al., 2012) . Values are expressed as percent lysis, with an untreated control serving as no lysis and an NP-40 incubated control serving as 100% lysis. For assays using recombinant vaccinia viruses expressing the LCMV NP or GP, target cells were infected with an MOI of 3.
Flow cytometric analysis
All flow cytometric analysis was performed on an LSR-II flow cytometer (BD Biosciences). Briefly, cells were stained for surface markers in PBS/1% FBS/0.1% sodium azide buffer prior to any intracellular staining. Intracellular staining was done using the BD Cytofix/Cytoperm kit to simultaneously fix and permeabilize the cells. Cells were incubated with Fc block prior to antibody staining to reduce background staining from Fc receptors. Antibody staining and FACS analysis on DCs were performed as previously reported (Sullivan et al., 2011; Walsh et al., 2012; Welch et al., 2012) .
Immunofluorescence staining of tissues and cells
Immunofluorescence staining of tissues was performed by collecting tissues and snap-freezing them on dry ice in embedding medium (OCT, Tissue-Tek). Tissues were cut into 6-μm sections using a Leica cryomicrotome and fixed with 4% paraformaldehyde. After fixation, sections were blocked with 10% fetal bovine serum in PBS, and then stained overnight at 4 1C with a 1:200 dilution of mouse monoclonal antibody against the LCMV NP. Tissues were washed and incubated for 1 h at 4 1C with a 1:200 solution of Alexa Fluor LASV Gp virus, and splenocytes were harvested at day 42 post-infection. After red blood cell lysis, splenocytes were counted and 2 Â 10 7 total memory splenocytes were injected i.p. into B6 mice infected at birth with either Clone 13 or rLCMV Cl13/ LASV Gp. Memory splenocytes were matched to the respective viruses; i.e. Clone 13 memory was injected into Clone 13 carrier mice. Serum viral titers were measured in the mice at the indicated timepoints by plaque assay. As the graph shows, titers of Clone 13 virus are significantly reduced (by 2.5 logs) in the mice by memory splenocytes at day 14 and totally purged by day 60 post-transfer (black circles). In contrast, the recombinant rLCMV Cl13/LASV Gp remains in the mouse at high titer beyond day 160 post-transfer (white circles).
488-conjugated anti-mouse IgG antibody (Life Technologies), and were then washed and mounted using VectaShield mounting medium (Vector Laboratories). Sections were imaged using a Zeiss Axiovert S100 immunofluorescence microscope fitted with an Axiocam color digital camera and 20 Â and 40 Â objectives. For immunofluorescence staining of cells, cells were washed to remove tissue culture medium and fixed in 4% paraformaldehyde for 10 min at room temperature. The cells were then blocked with PBS/1% FBS/0.1% saponin buffer, and incubated overnight at 4 1C with a 1:200 solution of anti-LCMV NP antibody. Cells were washed three times with PBS/1% FBS/0.1% saponin and incubated for 1 h at 4 1C with a 1:200 solution of Alexa Fluor 488-coupled anti-mouse IgG antibody. Cells were washed again and imaged using a 10x objective on the Zeiss Axiovert immunofluorescence microscope.
